Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Change in Receivables for 16 consecutive years, with $117491.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 29.77% year-over-year to $117491.0, compared with a TTM value of $515669.0 through Sep 2025, up 47.75%, and an annual FY2024 reading of $197708.0, down 78.92% over the prior year.
  • Change in Receivables was $117491.0 for Q3 2025 at China Pharma Holdings, up from $20566.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $434306.0 in Q1 2023 and bottomed at -$258130.0 in Q1 2022.
  • Average Change in Receivables over 5 years is $113378.1, with a median of $117491.0 recorded in 2025.
  • The sharpest move saw Change in Receivables tumbled 330.95% in 2021, then soared 578.17% in 2022.
  • Year by year, Change in Receivables stood at $393662.0 in 2021, then plummeted by 72.75% to $107286.0 in 2022, then soared by 239.52% to $364258.0 in 2023, then tumbled by 41.54% to $212942.0 in 2024, then plummeted by 44.82% to $117491.0 in 2025.
  • Business Quant data shows Change in Receivables for CPHI at $117491.0 in Q3 2025, $20566.0 in Q2 2025, and $164670.0 in Q1 2025.